{"title":"抗菌药物的发展:一个不断变化的景观:过时的监管方法和公司的流失正在让位于对抗生素的新兴趣和在临床中评估它们的创新方法","authors":"Alita A. Miller","doi":"10.1128/MICROBE.11.111.1","DOIUrl":null,"url":null,"abstract":"With annual deaths from antibiotic-resistant infections estimated at 23,000 in the United States (US), 25,000 in Europe, and much higher elsewhere, antibiotic resistance is among the most significant threats to human health. While overall public awareness of the problem does not reflect its gravity, increasing recognition of its magnitude by health authorities has led to several recent initiatives to address this crisis. Proposed solutions include eliminating use of antibiotics for growth promotion in livestock, enforcing antibiotic stewardship, improving surveillance, and ensuring a steady, robust pipeline of new, effective treatments, the latter of which is the focus of this article.","PeriodicalId":87479,"journal":{"name":"Microbe (Washington, D.C.)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1128/MICROBE.11.111.1","citationCount":"3","resultStr":"{\"title\":\"Antibacterial Development: a Changing Landscape: Outdated regulatory approaches and company attrition are giving way to renewed interest in antibiotics and innovative ways to evaluate them in the clinic\",\"authors\":\"Alita A. Miller\",\"doi\":\"10.1128/MICROBE.11.111.1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"With annual deaths from antibiotic-resistant infections estimated at 23,000 in the United States (US), 25,000 in Europe, and much higher elsewhere, antibiotic resistance is among the most significant threats to human health. While overall public awareness of the problem does not reflect its gravity, increasing recognition of its magnitude by health authorities has led to several recent initiatives to address this crisis. Proposed solutions include eliminating use of antibiotics for growth promotion in livestock, enforcing antibiotic stewardship, improving surveillance, and ensuring a steady, robust pipeline of new, effective treatments, the latter of which is the focus of this article.\",\"PeriodicalId\":87479,\"journal\":{\"name\":\"Microbe (Washington, D.C.)\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1128/MICROBE.11.111.1\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Microbe (Washington, D.C.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1128/MICROBE.11.111.1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Microbe (Washington, D.C.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1128/MICROBE.11.111.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Antibacterial Development: a Changing Landscape: Outdated regulatory approaches and company attrition are giving way to renewed interest in antibiotics and innovative ways to evaluate them in the clinic
With annual deaths from antibiotic-resistant infections estimated at 23,000 in the United States (US), 25,000 in Europe, and much higher elsewhere, antibiotic resistance is among the most significant threats to human health. While overall public awareness of the problem does not reflect its gravity, increasing recognition of its magnitude by health authorities has led to several recent initiatives to address this crisis. Proposed solutions include eliminating use of antibiotics for growth promotion in livestock, enforcing antibiotic stewardship, improving surveillance, and ensuring a steady, robust pipeline of new, effective treatments, the latter of which is the focus of this article.